3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Temozolomide
79
Magnetic Resonance Spectroscopy
68
Specimen Handling
45
Radiotherapy
42
Bevacizumab
29
Radiosurgery
27
Cyclophosphamide
27
Radiation
20
pembrolizumab
19
Blood Specimen Collection
19
fludarabine
16
Nivolumab
16
Irinotecan
15
Carboplatin
13
Biopsy
13
Etoposide
12
Vincristine
11
Pemetrexed
11
Lomustine
11
dinutuximab
9
Surgical Procedures, Operative
9
trametinib
8
abemaciclib
8
Ipilimumab
8
naxitamab
7
fluciclovine F-18
7
Watchful Waiting
7
Topotecan
7
Proton Therapy
7
Magnetic Resonance Imaging
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Interleukin-15
×
CNS
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled